文献速递MDS 与骨髓增殖性肿瘤白血病

Avapritinib治疗晚期系统性肥大细胞增多症:PATHFINDER研究4年随访

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.
PubMed 文献 · Blood Adv · 2026-01-01

PATHFINDER研究纳入107例晚期系统性肥大细胞增多症(AdvSM)患者,其中66%合并相关血液肿瘤(SM-AHN),接受Avapritinib 200 mg每日一次(起始剂量)口服治疗,中位随访49个月。总缓解率(ORR)为73%,中位缓解持续时间(DOR)58个月、无进展生存期(PFS)51个月、总生存期(OS)62个月,显示出深度且持久的缓解与可接受的风险获益特征。

要点

  • Avapritinib在AdvSM中ORR达73%,中位DOR 58个月、PFS 51个月、OS 62个月。
  • 疾病进展见于20%患者,主要发生于SM-AHN且多由相关血液肿瘤驱动。
  • 常见≥3级不良事件为血小板减少31%、贫血33%;颅内出血发生率4%(≥3级2%)。

核心结论

  • Avapritinib治疗AdvSM在4年随访中显示深度、持久的缓解和良好的风险获益特征。

研究设计与样本

  • PATHFINDER研究为完全入组的Avapritinib治疗AdvSM研究,共107例患者,中位随访49个月,83例可评估疗效。

主要发现

  • ORR为73%(95%CI 63-83);中位DOR 58个月、PFS 51个月、OS 62个月;107例中21例(20%)发生疾病进展,主要见于SM-AHN并由AHN驱动。

关键数值与推荐

  • Avapritinib起始剂量为200 mg每日一次口服;常见(≥30%患者)任何级别/≥3级治疗中出现的不良事件包括血小板减少(58%;31%)、眶周水肿(57%;6%)、贫血(54%;33%)、外周水肿(48%;2%)和腹泻(36%;5%)。

临床怎么用

  • 对于伴D816V突变KIT的AdvSM患者,Avapritinib可带来持久缓解,但需监测血小板减少、贫血等血液学毒性及认知效应和颅内出血。

局限性

  • 疗效可评估者为83/107例;疾病进展患者以SM-AHN为主,进展多由AHN驱动,需关注该亚组的管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Advanced systemic mastocytosis (AdvSM), a clonal hematologic neoplasm driven predominantly by D816V-mutant KIT, is often characterized by organ damage. Associated hematologic neoplasms (AHNs; usually myeloid) are often present, leading to poor survival. We report on the oral, highly selective, potent KIT D816V inhibitor avapritinib (200 mg once daily, starting dose) with >4 years follow-up from the fully enrolled PATHFINDER study. End points included overall response rate (ORR; primary), duration of response (DOR), progression-free survival (PFS), overall survival (OS), changes in objective biomarkers of disease, and safety (all secondary). Of 107 patients with AdvSM (including 71 [66%] with SM-AHN; overall population median follow-up, 49 months), 83 were response-evaluable. ORR was 73% (95% confidence interval, 63-83). Median DOR was 58 months; PFS, 51 months, and OS, 62 months. Disease progression occurred in 21 of 107 patients (20%), predominantly in SM-AHN and largely driven by the AHN. Reductions in objective biomarkers of disease were observed. Most frequent (≥30% patients) treatment-emergent adverse events (TEAEs; any grade; grade ≥3) were thrombocytopenia (58%; 31%); periorbital edema (57%; 6%), anemia (54%; 33%), peripheral edema (48%; 2%), and diarrhea (36%; 5%). Adverse events of special interest were cognitive effects (34%; 8%) and intracranial bleeds (4%; 2%). Eleven (10%) patients experienced TEAEs leading to death, of which 1 was deemed related to avapritinib by the principal investigator. With 4-year follow-up, patients with AdvSM treated with avapritinib experienced deep and durable responses and a favorable benefit-risk profile. This trial was registered at www.ClinicalTrials.gov as #NCT03580655.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Gotlib J, Reiter A, Radia DH, et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study. Blood Adv. 2026. PMID: 41604606. doi:10.1182/bloodadvances.2025017519

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。